Bilateral orchiectomy in the management of stage D-2 prostate cancer
- PMID: 8473090
Bilateral orchiectomy in the management of stage D-2 prostate cancer
Abstract
The records of 115 patients with stage D-2 prostate cancer treated with bilateral orchiectomy were reviewed to determine the effect of this procedure in previously untreated patients and in patients who had prior hormone therapy. Previously untreated patients survived 22.8 months while those who had prior hormone therapy survived 39.3 months (p < 0.001). Bilateral orchiectomy may be of additional clinical benefit in patients with advanced prostate cancer who have had prior hormone therapy.
Similar articles
-
Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer.Eur Urol. 1997;32 Suppl 3:81-5. Eur Urol. 1997. PMID: 9267791 Clinical Trial.
-
Mitomycin C for metastatic prostate cancer: final analysis of a randomized trial.Anticancer Res. 1999 May-Jun;19(3B):2157-61. Anticancer Res. 1999. PMID: 10472324 Clinical Trial.
-
[Treatment results of combined hormone and chemotherapy in patients with advanced prostate cancer].Hinyokika Kiyo. 1991 Aug;37(8):825-31. Hinyokika Kiyo. 1991. PMID: 1957724 Review. Japanese.
-
Hormone chemotherapy for newly diagnosed patients with metastatic prostate cancer.Int Urol Nephrol. 1993;25(5):469-74. Int Urol Nephrol. 1993. PMID: 8270375 Clinical Trial.
-
Reasons for delay of endocrine treatment in cancer of the prostate (until symptomatic metastases occur).Prog Clin Biol Res. 1990;359:7-14; discussion 15-24. Prog Clin Biol Res. 1990. PMID: 2284298 Review.
MeSH terms
Substances
LinkOut - more resources
Medical